All lobbying filings

VENN STRATEGIES

VENN STRATEGIES filed a Q4 report for UCB, INC. on January 20, 2026, reporting $80,000 in lobbying income.

Lobbying for UCB, INC. · Biopharmaceutical company dealing in severe diseases in immunology and neurology.

All filings by VENN STRATEGIES · Everything UCB, INC. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

Georgia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Policies related to biopharmaceutical access and innovation.

Taxation/Internal Revenue Code

International tax, corporate tax rate, and research and development tax issues.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.